Pharmacotherapeutic targeting of the angiopoietin system in sepsis, in addition to other cardiovascular disorders, is thus possible using chemical variants of Ang-1 that improve its pharmacokinetic and pharmacodynamic characteristics in vivo, allowing optimal delivery [50]. Here, ANGPT1 is linked to cardiovascular disorder.